Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now.

Following mixed results in the clinical trial of Ivonescimab, the company entered a new clinical collaboration with Revolution Medicines.

Summit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism

A laboratory employee in a sterile environment inspecting a microscope focused on a Clostridioides difficile infection sample.

The biopharma company, Summit Therapeutics Inc. (NASDAQ:SMMT) develops oncology therapies. Its lead candidate, Ivonescimab, targeting PD-1 and VEGF, is in clinical trials for non-small cell lung cancer. The Miami-based company currently holds regulatory collaborations for commercialization across multiple global regions.

On May 30, 2025, Summit Therapeutics Inc. (NASDAQ:SMMT) announced mixed results from the trial of its antibody treatment for lung cancer, Ivonescimab. In a comparison study, the drug had initially performed better than Merck’s Keytruda. But the latest evaluation revealed both promising and less favourable outcomes.

Later, on June 30, 2025, the company entered a new clinical collaboration with Revolution Medicines to evaluate combinations of three RAS(ON) inhibitors with Ivonescimab in RAS mutant tumours. The aim is to assess the safety and efficacy of these combinations across three priority tumour types, including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC).

Initial study stands positive with evidence suggesting that Revolution Medicines’ inhibitors in combination with a PD-1 antibody can deliver additive antitumor activity safely in patients with RAS mutant NSCLC. This has created anticipation for further therapeutic benefits with novel PD-1 bispecific inhibitors like Ivonescimab.

With favorable developments triggering sharp upside movements, the company’s short float of 25.63% remains attractive to short-squeeze investors.

While we acknowledge the risk and potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best REIT Stocks to Buy Right Now and 10 Stocks with Huge Catalysts on the Horizon

Disclosure. None.